Delma Caiati
Stock Analyst at Guggenheim
(1.54)
# 3,108
Out of 5,162 analysts
14
Total ratings
50%
Success rate
-0.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Delma Caiati
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LBRX LB Pharmaceuticals | Reiterated: Buy | $80 | $42.46 | +88.41% | 5 | Nov 13, 2026 | |
| RAPP Rapport Therapeutics | Reiterated: Buy | $70 → $66 | $25.85 | +155.32% | 3 | Nov 4, 2026 | |
| NBIX Neurocrine Biosciences | Reiterated: Buy | $207 → $224 | $169.40 | +32.23% | 2 | Nov 3, 2026 | |
| XENE Xenon Pharmaceuticals | Reiterated: Buy | $73 | $41.00 | +78.07% | 2 | Oct 29, 2026 | |
| MPLT MapLight Therapeutics | Initiated Coverage: Hold | n/a | $7.07 | - | 1 | Oct 5, 2026 | |
| OVID Ovid Therapeutics | Initiated Coverage: Buy | $7 | $2.55 | +174.51% | 1 | Oct 5, 2026 |
LB Pharmaceuticals
Nov 13, 2026
Reiterated: Buy
Price Target: $80
Current: $42.46
Upside: +88.41%
Rapport Therapeutics
Nov 4, 2026
Reiterated: Buy
Price Target: $70 → $66
Current: $25.85
Upside: +155.32%
Neurocrine Biosciences
Nov 3, 2026
Reiterated: Buy
Price Target: $207 → $224
Current: $169.40
Upside: +32.23%
Xenon Pharmaceuticals
Oct 29, 2026
Reiterated: Buy
Price Target: $73
Current: $41.00
Upside: +78.07%
MapLight Therapeutics
Oct 5, 2026
Initiated Coverage: Hold
Price Target: n/a
Current: $7.07
Upside: -
Ovid Therapeutics
Oct 5, 2026
Initiated Coverage: Buy
Price Target: $7
Current: $2.55
Upside: +174.51%